Allarity Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Allarity Therapeutics (ALLR).

Price Target Range — 4 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$11Upside to Avg. PT+1122.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 16, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$10→$11
Jun 8, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$10→$10
Apr 10, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$10→$10
Dec 9, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$9→$10
Sep 26, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$9→$9
Jul 28, 2025	Ascendiant Capital	Edward Woo	Initiate	Buy	$9

More with Benzinga EdgeGet Access

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.5 to $9.75.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target from $9 to $9.25.

Benzinga Newsdesk

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

Allarity Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Allarity Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

People Also Watch

People Also Watch

Allarity Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Allarity Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

PROAscendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

PROAscendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

PROAscendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

PROAscendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25